Brii Biosciences snaps up VBI Vaccines' HBV programs in expanded deal, jumping into commercial mode

Amber Tong

Five years after bagging China rights to VBI Vaccines’ hepatitis B therapy and teaming up on its development, Brii Biosciences is going for the whole …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Brii Biosciences snaps up VBI Vaccines' HBV programs in expanded deal, jumping into commercial mode

Amber Tong

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

Sofinnova outlines $550M fund after IPOs and M&A deals

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

Brii Bio­sciences snaps up VBI Vac­ci­nes' HBV pro­grams in ex­pand­ed deal, jump­ing in­to com­mer­cial mode

Amber Tong

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Brii Biosciences snaps up VBI Vaccines' HBV programs in expanded deal, jumping into commercial mode

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

Sofinnova outlines $550M fund after IPOs and M&A deals

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.